December 16, 2012
In the Region Fewer PGW terminations Philadelphia Gas Works said Friday that 7,742 of its 479,000 residential customers are without gas service after their accounts were terminated earlier in the year for failure to pay, a reduction of 781 customers from the same time a year ago. The city-owned utility reported the numbers in its annual cold weather survey that it is required to submit to the Pennsylvania Public Utility Commission....
April 15, 2008 |
LONDON - Shares in pharmaceutical company AstraZeneca PLC soared today on news that an agreement with an Indian company will delay the release of a generic competitor to its best selling heartburn drug for six years. AstraZeneca said financial guidance for 2008 would remain unchanged, but the company's shares shot up almost 9 percent as analysts sensed less of a profit risk for the London-based drug maker. India's Ranbaxy Laboratories Ltd. had submitted an application to the U.S. Food and Drug Administration to make a generic version of esomeprazole magnesium, the active pharmaceutical ingredient in heartburn medicine Nexium.
October 7, 2011 |
AstraZeneca P.L.C., the global pharmaceutical giant that makes well-known medicines such as Prilosec, Nexium, and Seroquel, said Thursday it would cut about 400 U.S. jobs, with most of the layoffs at its headquarters in Wilmington. About 330 people will lose jobs and 70 vacant positions will be eliminated as the company continues to pare its costs to sustain profits. The company said the job cuts would come from headquarters staff and "some field-based, non-sales roles," elsewhere in the country.
April 26, 2012 |
AstraZeneca P.L.C. chief executive officer David Brennan said Thursday he would retire June 1 in the wake of another difficult quarter for the pharmaceutical manufacturer. Based in the United Kingdom, AstraZeneca has its U.S. headquarters in Wilmington and a plant in Newark, Del. The company has struggled lately as it tried to replace revenue, some of which has been lost as blockbuster drugs face generic competition because their patents are expiring. AstraZeneca's best-selling drugs are Crestor (cardiovascular)
October 20, 2000 |
It is the world's best-selling prescription drug, and for some, the bright purple pill Prilosec has become a daily essential they call Vitamin P. And like vitamins, Prilosec may soon be available without a prescription. Today, AstraZeneca P.L.C., the British drugmaker with U.S. headquarters in Wilmington, will go before a Food and Drug Administration committee to seek approval to sell an over-the-counter version of its Prilosec, a treatment for such stomach disorders as ulcers and heartburn.
April 24, 2007 |
After a series of setbacks in developing products, AstraZeneca P.L.C. said today that it would pay $15.2 billion in cash to buy MedImmune Inc. in order to gain biotechnology medicines and enter the vaccines business. AstraZeneca - Britain's second-largest drugmaker, with U.S. headquarters and about 4,500 employees near Wilmington - will pay $58 a share for MedImmune, which is a 21 percent premium to the Gaithersburg, Md., company's closing price Friday of $48.01. The deal will increase AstraZeneca's proportion of biologics drugs, derived from organisms, from 7 percent to 27 percent, add 45 products in development, and give AstraZeneca the influenza vaccine FluMist and the children's respiratory treatment Synagis.
April 9, 2009 |
A government panel opened the door a crack yesterday toward allowing AstraZeneca P.L.C. to sell its Seroquel XR more widely, after an emotional meeting that included stories from two families who say their loved ones died after taking the powerful antipsychotic. The Food and Drug Administration advisory committee recommended the agency approve Seroquel XR for use as an additional therapy in patients suffering from depression who do not respond adequately to their current medications.
April 26, 2011 |
When I'd heard that AstraZeneca P.L.C. was not only cutting jobs in Wilmington, but also tearing down buildings, it sounded like a corporate variation on scorched-earth tactics. The News Journal broke the news last week that the pharmaceutical company plans to raze 450,000 square feet of laboratory space in three buildings at its Wilmington-area campus over the next two years. Most companies, when they resort to layoffs, don't level the buildings, too. It sounded to me to be a little drastic.
May 3, 2007 |
Federal regulators said yesterday that they are reviewing AstraZeneca P.L.C.'s handling of alleged improper marketing and the firing of a sales director. The U.S. Department of Health and Human Services made the comment in response to the drug company's statement yesterday that it had concluded an internal investigation and would share findings with regulators. "We expect to receive further information from AstraZeneca and will follow up with them as appropriate," a department spokesman, Donald White, said, giving no more details.
July 27, 2007 |
AstraZeneca P.L.C. said yesterday that it would lay off an additional 4,600 employees, trimming its payroll 7,600, or 11 percent of its workforce, within three years. The London-based drugmaker announced in February that it would dismiss about 3,000 employees in operations and manufacturing. The company said it decided additional cuts were needed in European sales and marketing, information services and business support, and drug research and development. "We still haven't finished exploring further opportunities to reduce our cost base and improve future profitability," chief financial officer Jon Symonds told investors and analysts.